T. Rowe Price Associates
CKPT

T. Rowe Price Associates’s Checkpoint Therapeutics CKPT Stock Holding History

T. Rowe Price Associates’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,900
Closed -$62K – 2939
2022
Q3 		$62K Hold
5,900
– – ﹤0.01% 2802
2022
Q2 		$61K Hold
5,900
– – ﹤0.01% 2835
2022
Q1 		$104K Buy
+5,900
New +$127K ﹤0.01% 2840

Other funds holding CKPT

TC
TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's CKPT Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 5,900 shares — an estimated $62K sold.

T. Rowe Price Associates first reported a position in CKPT in Q1 2022 and held it in 3 quarters. The position peaked at $104K in Q1 2022. 40 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 5,900 Checkpoint Therapeutics shares in Q4 2022, an estimated $62K.
  • T. Rowe Price Associates first reported a position in Checkpoint Therapeutics in Q1 2022 and held it in 3 quarters.
  • T. Rowe Price Associates's Checkpoint Therapeutics position peaked at $104K in Q1 2022.
  • 40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.